Search

Your search keyword '"Amylou C. Dueck"' showing total 12 results
Start Over "Amylou C. Dueck" Topic oncology Database Complementary Index
12 results on '"Amylou C. Dueck"'

1. Studies from University of North Carolina Update Current Data on Cancer [Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39)].

Subjects
RANDOMIZED controlled trials, CANCER prognosis, CANCER treatment, CLINICAL trials monitoring, MEDICAL research, CLINICAL trials
Abstract

Keywords: Cancer; Clinical Research; Clinical Trials and Studies; Health and Medicine; Investment and Finance; Oncology EN Cancer Clinical Research Clinical Trials and Studies Health and Medicine Investment and Finance Oncology 1523 1523 1 09/11/23 20230911 NES 230911 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on cancer is now available. According to news reporting out of Chapel Hill, North Carolina, by NewsRx editors, research stated, "Financial toxicity (FT) affects 20% of cancer survivors and is associated with poor clinical outcomes. [Extracted from the article]

Published
2023

2. Research from University of North Carolina in the Area of Rectal Cancer Published [Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)].

Subjects
RECTAL cancer, PATIENT reported outcome measures, ABDOMINOPERINEAL resection, THERAPEUTICS, RECTAL surgery
Abstract

Cancer, Drugs and Therapies, Gastroenterology, Health and Medicine, Oncology, Rectal Cancer, Surgery Keywords: Cancer; Drugs and Therapies; Gastroenterology; Health and Medicine; Oncology; Rectal Cancer; Surgery EN Cancer Drugs and Therapies Gastroenterology Health and Medicine Oncology Rectal Cancer Surgery 1099 1099 1 06/19/23 20230620 NES 230620 2023 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Fresh data on rectal cancer are presented in a new report. [Extracted from the article]

Published
2023

3. Successes and lessons learned in database development for national multi-site cancer care delivery research trials: the Alliance for Clinical Trials in Oncology experience.

Author

Zahrieh, David, Hillman, Shauna L., Tan, Angelina D., Frank, Jennifer L., Dockter, Travis, Meyers, Bobbi Jo, Cherevko, Cassie L., Peil, Elizabeth S., McCue, Shaylene, Kour, Oudom, Gunn, Heather J., Neuman, Heather B., Chang, George J., Paskett, Electra D., Mandrekar, Sumithra J., and Dueck, Amylou C.

Subjects
DATABASE design, CLINICAL trials, CANCER treatment, DATA management, ONCOLOGY
Abstract

Introduction: Alliance for Clinical Trials in Oncology (Alliance) coordinated trials utilize Medidata Rave® (Rave) as the primary clinical data capture system. A growing number of innovative and complex cancer care delivery research (CCDR) trials are being conducted within the Alliance with the aims of studying and improving cancer-related care. Because these trials encompass patients, providers, practices, and their interactions, a defining characteristic of CCDR trials is multilevel data collection in pragmatic settings. Consequently, CCDR trials necessitated innovative strategies for database development, centralized data management, and data monitoring in the presence of these real-world multilevel relationships. Having real trial experience in working with community and academic centers, and having recently implemented five CCDR trials in Rave, we are committed to sharing our strategies and lessons learned in implementing such pragmatic trials in oncology.Methods: Five Alliance CCDR trials are used to describe our approach to analyzing the database development needs and the novel strategies applied to overcome the unanticipated challenges we encountered. The strategies applied are organized into 3 categories: multilevel (clinic, clinic stakeholder, patient) enrollment, multilevel quantitative and qualitative data capture, including nontraditional data capture mechanisms being applied, and multilevel data monitoring.Results: A notable lesson learned in each category was (1) to seek long-term solutions when developing the functionality to push patient and non-patient enrollments to their respective Rave study database that affords flexibility if new participant types are later added; (2) to be open to different data collection modalities, particularly if such modalities remove barriers to participation, recognizing that additional resources are needed to develop the infrastructure to exchange data between that modality and Rave; and (3) to facilitate multilevel data monitoring, orient site coordinators to the their trial's multiple study databases, each corresponding to a level in the hierarchy, and remind them to establish the link between patient and non-patient participants in the site-facing NCI web-based enrollment system.Conclusion: Although the challenges due to multilevel data collection in pragmatic settings were surmountable, our shared experience can inform and foster collaborations to collectively build on our past successes and improve on our past failures to address the gaps. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

4. Studies Conducted at Mayo Clinic on Cancer Recently Reported [Statistical Properties of Items and Summary Scores From the Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (Pro-ctcae(R)) In a Diverse Cancer...].

Subjects
REPORTERS & reporting, PATIENTS' attitudes, ELECTRONIC records, XEROSTOMIA, STANDARD deviations
Abstract

A recent study conducted at Mayo Clinic in Scottsdale, Arizona, focused on the statistical properties of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a diverse sample of cancer patients. The research analyzed data from 899 patients with various cancer types and found that most patients reported experiencing adverse events such as fatigue, sadness, anxiety, pain, insomnia, and dry mouth. The study concluded that the full complement of attributes should be administered for each adverse event, and both attributes and summary scores should be reported. This research has been peer-reviewed and provides valuable insights for PRO-CTCAE administration and reporting practices. [Extracted from the article]

Published
2024

5. Research from University of Texas MD Anderson Cancer Center Broadens Understanding of Mesotheliomas (Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural...).

Subjects
SYMPTOM burden, CLINICAL trials, PLEURA cancer, UNIVERSITY research, SYMPTOMS, MEDICAL research
Abstract

A recent study conducted at the University of Texas MD Anderson Cancer Center has developed a composite symptom score (CSS) to measure disease-related symptom burden in patients with malignant pleural mesothelioma (MPM). The CSS was created using longitudinal data from a Phase IIB study, and it includes five MPM symptoms: pain, fatigue, shortness of breath, muscle weakness, and coughing. The CSS was found to correlate strongly with other symptom scales and demonstrated good sensitivity to worsening disease and quality of life ratings. This CSS can be used as an outcome measure in MPM clinical trials and has the potential to be adapted for other advanced-cancer trials. [Extracted from the article]

Published
2024

6. Patient-reported quality-of-life outcomes in relation to provider-assessed adverse events during head and neck radiotherapy.

Author

Niska, Joshua R., Thorpe, Cameron S., Halyard, Michele Y., Tan, Angelina D., Atherton, Pamela J., Dueck, Amylou C., Patel, Samir H., and Sloan, Jeff A.

Subjects
SELF-evaluation, RADIOTHERAPY, KRUSKAL-Wallis Test, BLAND-Altman plot, ONCOLOGY, SOCIAL participation, WELL-being, ATTITUDES of medical personnel, HEAD & neck cancer, HEALTH outcome assessment, TREATMENT effectiveness, CANCER patients, QUALITY of life, CANCER fatigue, DESCRIPTIVE statistics
Abstract

Purpose: To assess the relationship between patient-reported quality-of-life (QOL) outcomes and provider-assessed adverse events (AEs) during head-and-neck (H&N) radiotherapy (RT). Methods: Sixty-five patients undergoing H&N RT prospectively completed 12-domain linear analogue self-assessments (LASA) at baseline, before biweekly appointments, and at last week of RT. At the same time points, provider-assessed AEs were graded using Common Terminology Criteria for Adverse Events v4.0. LASA scores were stratified by maximum-grade AE and analyzed using Kruskal-Wallis methodology. Agreement between LASA scores and maximum-grade AE was assessed using Bland-Altman analysis. Results: Patient-reported QOL outcomes showed clinically meaningful decreases in most domains, predominantly fatigue (77.8% of patients), social activity (75.4%), and overall QOL (74.2%). Provider-assessed AEs showed 100% grade 2 AE, 35.4% grade 3 AE, and 3.1% grade 4 AE. At baseline, patients with higher grade AEs reported worse physical well-being (WB) (P =.04). At week 1, the following QOL domains were worse for patients with higher grade AEs: overall QOL (P =.03), mental WB (P =.02), and physical WB (P =.03). Bland-Altman analysis showed that QOL scores were relatively worse than AE burden at baseline and relatively better at RT completion. Conclusions: Worse QOL was associated with higher-grade AEs at baseline and early in RT. The impact of AEs on QOL appears to lessen with time. Patient-reported QOL outcomes and provider-assessed AEs provide complementary information. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

7. Research on Cancer Published by Researchers at Yale University School of Medicine [Integrating 4 methods to evaluate physical function in patients with cancer (In4M): protocol for a prospective cohort study].

Subjects
PHYSICAL mobility, RESEARCH personnel, CANCER patients, LONGITUDINAL method, CANCER research
Abstract

A report from Yale University School of Medicine discusses the importance of accurately evaluating physical function in cancer patients. The study aims to integrate multiple assessment methods, including clinician-reported outcomes, patient-reported outcomes, performance outcome tests, and wearable data, to gather comprehensive information on the functional impacts experienced by patients. The research will enroll 200 English-speaking and/or Spanish-speaking patients with breast cancer or lymphoma who will receive chemotherapy. The study has received approval from relevant ethics boards and will provide results to participants, funders, the research community, and the public. [Extracted from the article]

Published
2024

9. University of Texas Researcher Yields New Findings on Pancreatic Cancer [Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)].

Subjects
NEOADJUVANT chemotherapy, PANCREATIC cancer, CLINICAL trials, RESEARCH personnel, COMBINED modality therapy
Abstract

Keywords: Adverse Drug Reactions; Cancer; Clinical Research; Clinical Trials and Studies; Combined Modality Therapy; Drugs and Therapies; Gastroenterology; Health and Medicine; Neoadjuvant Therapy; Oncology; Pancreas; Pancreatic Cancer; Pancreatic Neoplasms; Pharmaceuticals; Radiotherapy EN Adverse Drug Reactions Cancer Clinical Research Clinical Trials and Studies Combined Modality Therapy Drugs and Therapies Gastroenterology Health and Medicine Neoadjuvant Therapy Oncology Pancreas Pancreatic Cancer Pancreatic Neoplasms Pharmaceuticals Radiotherapy 1135 1135 1 09/25/23 20230925 NES 230925 2023 SEP 26 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on pancreatic cancer. For more information on this research see: Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501). [Extracted from the article]

Published
2023

10. Findings from Mayo Clinic Provide New Insights into Disease Progression (Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma).

Subjects
PARAGANGLIOMA, TEMOZOLOMIDE, DISEASE progression, OLAPARIB, PHEOCHROMOCYTOMA, SINGLE-strand DNA breaks
Abstract

Keywords: Alkylating Agents; Antineoplastics; Cancer; Clinical Research; Clinical Trials and Studies; Disease Attributes; Disease Progression; Drugs and Therapies; Endocrinology; Health and Medicine; Olaparib Therapy; Oncology; Paragangliomas; Pharmaceuticals; Pheochromocytoma; Poly(ADP-Ribose) Polymerase Inhibitors; Temozolomide Therapy EN Alkylating Agents Antineoplastics Cancer Clinical Research Clinical Trials and Studies Disease Attributes Disease Progression Drugs and Therapies Endocrinology Health and Medicine Olaparib Therapy Oncology Paragangliomas Pharmaceuticals Pheochromocytoma Poly(ADP-Ribose) Polymerase Inhibitors Temozolomide Therapy 299 299 1 06/19/23 20230619 NES 230619 2023 JUN 20 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on disease progression have been published. According to news originating from Rochester, Minnesota, by NewsRx correspondents, research stated, "TPS4191: Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare neuroendocrine tumors (NETs) that arise from chromaffin cells. [Extracted from the article]

Published
2023

11. Investigators at University Hospital Wurzburg Detail Findings in Acute Myeloid Leukemia (Phase 1/1b Study of Azacitidine and Hedgehog Pathway Inhibitor Sonidegib In Patients With Myeloid Neoplasms).

Subjects
ACUTE myeloid leukemia, HEDGEHOG signaling proteins, UNIVERSITY hospitals, TUMORS, AZACITIDINE, MYELODYSPLASTIC syndromes
Abstract

Keywords: Wurzburg; Germany; Europe; Acute Myeloid Leukemia; Antineoplastics; Aza Compounds; Azacitidine; Azacitidine Therapy; Cancer; Drugs and Therapies; Health and Medicine; Hedgehog Pathway Inhibitor; Hematology; Leukemia; Neoplasms; Oncology; Pharmaceuticals; Smoothened Receptor Antagonists EN Wurzburg Germany Europe Acute Myeloid Leukemia Antineoplastics Aza Compounds Azacitidine Azacitidine Therapy Cancer Drugs and Therapies Health and Medicine Hedgehog Pathway Inhibitor Hematology Leukemia Neoplasms Oncology Pharmaceuticals Smoothened Receptor Antagonists 830 830 1 05/29/23 20230602 NES 230602 2023 JUN 2 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Oncology - Acute Myeloid Leukemia. Wurzburg, Germany, Europe, Acute Myeloid Leukemia, Antineoplastics, Aza Compounds, Azacitidine, Azacitidine Therapy, Cancer, Drugs and Therapies, Health and Medicine, Hedgehog Pathway Inhibitor, Hematology, Leukemia, Neoplasms, Oncology, Pharmaceuticals, Smoothened Receptor Antagonists. [Extracted from the article]

Published
2023

12. Recommendations for including multiple symptoms as endpoints in cancer clinical trials.

Author

Cleeland, Charles S., Sloan, Jeff A., Cella, David, Chen, Connie, Dueck, Amylou C., Janjan, Nora A., Liepa, Astra M., Mallick, Rajiv, O'Mara, Ann, Pearson, Jay D., Torigoe, Yasuhiro, Wang, Xin Shelley, Williams, Loretta A., and Woodruff, Jeanie F.

Subjects
CLINICAL trials, CANCER treatment, HEALTH outcome assessment, ONCOLOGY, MEDICAL records, HEALTH policy
Abstract

The multiple symptoms arising from cancer and its treatment impose significant distress for patients. However, in clinical research, there is no agreed-upon way of assessing and presenting the effects of treatment on multiple symptoms, as either individual scores or a composite score. The ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force was established to make recommendations about measuring multiple symptoms as outcomes in cancer clinical trials. The Multisymptom Task Force addressed how to choose the symptoms to be assessed and how multiple individual symptom scores or composite scores of several symptoms might be used as clinical trial outcomes. Consensus was reached on a definition of a multisymptom outcome, the problem of source attribution, and the need for a hypothesis-driven conceptual framework to measure multisymptom outcomes. Validated single-item and multi-item measures currently available or that can be easily generated for oncology use were deemed sufficient for measuring multiple symptoms. The relative value of a composite score versus a set of individual symptom scores was discussed, along with issues in developing and deploying such a composite measure. The results indicated that more research on combining scores of different symptoms is needed. Symptom data should be a required component of cancer clinical trials. Patient-reported symptoms provide a unique patient perspective on treatment benefit and risk that goes beyond clinician-reported adverse events. A representation of changes in multiple symptoms would clarify the impact of treatment and enhance the interpretation of cancer clinical trials for clinicians, patients, and those who make health care policy. Cancer 2013. © 2012 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results